Lowering Prescription Drug Costs by Removing Barriers to Challenging Patents
Amicus Brief Filed in RPX Corp. v. Chanbond LLC: Patient and public interest actors should have the same rights as drugmakers to appeal IPR decisions to the courts to prevent unmerited patents.
Letter to the USPTO Director
Policy Prescriptions to Solve the Drug Patent Problem
Submission to Chinese FDA: more exclusivity will harm patients
Impact of civil society patent oppositions
Presentation by Tahir Amin at the Global Summit on Intellectual Property & Access to Medicines in the roundtable session “Challenging unmerited patents.”
Civil Society and Patent Oppositions
Presentation by Tahir Amin at the Global Summit on Intellectual Property & Access to Medicines in the plenary session “The role of civil society in the TRIPS flexibilities implementation.”
Argentina SOF Prodrug Decision
La impugnación de patentes: protección del dominio público y acceso a medicamentos asequibles”, Archipiélago, Cuadernos De Crítica De La Cultura (The Patent Challenge: Protecting the Public Domain and Access to Medicines, Archipielago Journal)
Original article in Spanish English translation